Circannual variability in adrenocorticotropic hormone responses to administration of thyrotropin-releasing hormone in clinically normal horses in Australia.

Thyrotropin releasing hormone (TRH)-stimulation testing for pituitary pars intermedia dysfunction (PPID) in horses is only recommended at certain times of the year. Current diagnostic cut-off values reflect testing in the northern hemisphere during this time. The aims of this study were to evaluate TRH stimulation testing during two different phases of the circannual pituitary cycle and to determine whether diagnostic cut-off values developed in the northern hemisphere are appropriate in Australia. Thirteen clinically normal horses at Perth, Western Australia, and 23 horses at Townsville, Queensland, Australia, had TRH stimulation tests performed at two different time points during the circannual pituitary cycle. At both locations, post-TRH adrenocorticotropic hormone (ACTH) concentrations were significantly different between testing time points (Perth: P=0.001; Townsville: P<0.0001). In Perth, the mean ACTH concentrations 10min post-TRH in September and March were 51.4pg/mL (95% confidence interval, CI, 46.4-56.4pg/mL) and 248.5pg/mL (95% CI 170.2-326.9pg/mL), respectively. The median percentage change in ACTH concentrations in March was 361.9%. In Townsville, the mean ACTH concentrations 30min post-TRH in September and April were 35.3pg/mL (95% CI 29.6-40.9pg/mL) and 112.3pg/mL (95% CI 93.4-131.2pg/mL), respectively. The median percentage change in ACTH concentrations in April was 144.7%. The ACTH cut-off value after TRH stimulation in normal horses in September in Perth and Townsville was similar to the values established in the northern hemisphere. However, TRH stimulation testing in March/April was highly variable at both locations.

The Effect of Geographic Location on Circannual Adrenocorticotropic Hormone Plasma Concentrations in Horses in Australia.

BACKGROUND: Longitudinal evaluation of plasma endogenous ACTH concentration in clinically normal horses has not been investigated in the Southern Hemisphere. OBJECTIVES: To longitudinally determine monthly upper reference limits for plasma ACTH in 2 disparate Australian geographic locations and to examine whether location affected the circannual rhythm of endogenous ACTH in the 2 groups of horses over a 12-month period. ANIMALS: Clinically normal horses <20 years of age from 4 properties (institutional herd and client owned animals) in Perth (n = 40) and Townsville (n = 41) were included in the study. METHODS: A prospective longitudinal descriptive study to determine the upper reference limit and confidence intervals for plasma ACTH in each geographic location using the ASVCP reference interval (RI) guidelines, for individual months and monthly groupings for 12 consecutive months. RESULTS: Plasma endogenous ACTH concentrations demonstrated a circannual rhythm. The increase in endogenous ACTH was not confined to the autumnal months but was associated with changes in photoperiod. During the quiescent period, plasma ACTH concentrations were lower, ≤43 pg/mL (upper limit of the 90% confidence interval (CI)) in horses from Perth and ≤67 pg/mL (upper limit of the 90% CI) in horses from Townsville, than at the acrophase, ≤94 pg/mL (upper limit of the 90% CI) in horses from Perth, ≤101 pg/mL (upper limit of the 90% CI) in horses from Townsville. CONCLUSIONS AND CLINICAL IMPORTANCE: Circannual rhythms of endogenous ACTH concentrations vary between geographic locations, this could be due to changes in photoperiod or other unknown factors, and upper reference limits should be determined for specific locations.

Racing performance following prosthetic laryngoplasty using a polyurethane prosthesis combined with a laser-assisted ventriculocordectomy for treatment of recurrent laryngeal neuropathy in 78 Thoroughbred racehorses.

REASONS FOR PERFORMING STUDY: Recurrent laryngeal neuropathy (RLN) causes airway obstruction and adversely affects racing performance in Thoroughbred racehorses. Prosthetic laryngoplasty (PL) is the preferred treatment of RLN as it returns variables of airway mechanics to baseline. A number of materials have been evaluated as prostheses; however, the application of Lycra has not been rigorously investigated. OBJECTIVE: To evaluate the efficacy of PL using a Lycra prosthesis, in combination with transendoscopic, laser-assisted ventriculocordectomy, to restore racing performance in Thoroughbred racehorses with RLN. STUDY DESIGN: Retrospective case series. METHODS: Medical records, preoperative and post operative racing performance indices from 78 Thoroughbred racehorses that underwent surgical treatment for RLN were evaluated. Medical records, preoperative and post operative racing performance indices were evaluated. Case history, postoperative complications and PL failure were recorded. Racing performance was analysed using Beyer Speed Figures (BSF), earnings and a performance index (PI), with comparisons made between the 3 races before and after surgery. Factors associated with return to racing and racing performance were analysed. RESULTS: Eighty-two per cent (46/56) of horses that raced prior to surgery and 75% (15/20) of horses that had not raced prior to surgery competed in at least one race post operatively. Horses had a lower BSF and PI in the final race before surgery. Following surgery, PI and BSF values were restored to preoperative values in 73% and 78% of horses respectively. Surgical failure rate and immediate post operative complication rate were lower than, or comparable with,other reported prosthesis materials. CONCLUSIONS: Thoroughbred racehorses with RLN have a good prognosis for racing successfully after PL using a Lycra prosthesis. The described surgical technique is associated with a low post operative complication rate and an increase in indicators of racing performance (PI and BSF) post operatively. Lycra offers an attractive option for application as a prosthetic for PL with a low complication rate and similar efficacy to reported rigid prostheses.

Effects of the insulin-sensitizing drug pioglitazone and lipopolysaccharide administration on insulin sensitivity in horses.

BACKGROUND: Obesity and insulin resistance increase the risk of laminitis in horses. Pioglitazone (PG) is an insulin-sensitizing drug used in humans that is absorbed after oral administration to horses. HYPOTHESIS: PG treatment will increase insulin sensitivity and transcript abundance of glucose and lipid transporters in adipose and skeletal muscle tissues. ANIMALS: Sixteen lean, healthy horses. METHODS: Eight horses were administered PG (1 mg/kg bodyweight PO) for 12 days before induction of insulin resistance through IV administration of lipopolysaccharide (LPS). Treated and untreated controls (CN; n = 8) were subjected to testing of peripheral insulin sensitivity and biopsies of both subcutaneous (nuchal ligament) adipose tissue and skeletal muscle before and after treatment, and 24 hours after LPS administration. RESULTS: PG treatment did not improve basal insulin sensitivity (CNs: 1.4 ± 0.3, PG-treated: 1.9 ± 1.3; P > .4) or mitigate LPS-induced insulin resistance (CNs: 0.4 ± 0.3, PG-treated: 0.4 ± 0.3); however, transcript abundance of glucose and lipid transporters was altered in both skeletal muscle and subcutaneous adipose tissue. CONCLUSIONS AND CLINICAL IMPORTANCE: Either a higher dose or longer treatment period might be required for physiological effects to be observed. PG is a novel therapeutic agent requiring further investigation in horses in order to determine treatment efficacy.